OraSure Technologies IncOSUR
± MixedCapitalrelevance
First GAAP profit in years driven by liability reduction, but core losses persist and cash declined.
Impact on stocks 2
Biotech & Genomic Medicine
OraSure Technologies IncAging Population
OraSure Technologies reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier, though the profit came almost entirely from a $22.6 million reduction in a contingent consideration liability tied to a regulatory setback. Revenue of $30.6 million beat guidance and climbed 9.7% from the prior quarter, but total revenue was still down 2% year over year, and core revenue was flat. Diagnostics revenue grew 1% to $19.4 million, helped by higher syphilis test sales and the BioMedomics Sickle SCAN product line, while the company won FDA clearance for its Colli-Pee Dx urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 test. However, non-GAAP operating loss widened to $14.7 million from $13.2 million, and non-GAAP net loss was $13.8 million, roughly in line with last year's $14.2 million loss. The company also withdrew its InteliQuick CT/NG molecular self-test submission after FDA feedback, delaying that product's path to market, and cash and equivalents fell to $161 million from $199.3 million at the end of 2025.
OraSure Technologies IncFirst GAAP profit in years driven by liability reduction, but core losses persist and cash declined.
